JPMorgan Chase & Co. bought a new position in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,199,300 shares of the biopharmaceutical company’s stock, valued at approximately $7,915,000. JPMorgan Chase & Co. owned about 2.33% of Tetraphase Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in TTPH. American International Group Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 44.1% in the 3rd quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,345 shares during the last quarter. Brighton Jones LLC bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at $108,000. SG Americas Securities LLC bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at $107,000. Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 21.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 235,309 shares of the biopharmaceutical company’s stock valued at $1,609,000 after acquiring an additional 41,165 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its stake in Tetraphase Pharmaceuticals by 95.5% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 393,000 shares of the biopharmaceutical company’s stock valued at $2,688,000 after acquiring an additional 192,000 shares in the last quarter. 58.15% of the stock is currently owned by institutional investors.

Several analysts have weighed in on TTPH shares. HC Wainwright lifted their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. ValuEngine cut Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. BMO Capital Markets lifted their price target on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $15.15.

Tetraphase Pharmaceuticals, Inc. (NASDAQ TTPH) opened at $6.26 on Wednesday. The stock has a market capitalization of $323.91, a price-to-earnings ratio of -2.18 and a beta of 2.51. Tetraphase Pharmaceuticals, Inc. has a 1-year low of $3.57 and a 1-year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.58) EPS. research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current year.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage bought 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “1,199,300 Shares in Tetraphase Pharmaceuticals, Inc. (TTPH) Purchased by JPMorgan Chase & Co.” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/12/27/1199300-shares-in-tetraphase-pharmaceuticals-inc-ttph-purchased-by-jpmorgan-chase-co.html.

Tetraphase Pharmaceuticals Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.